Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Mark_A._Goldsmith
|
| gptkbp:collaboratesWith |
gptkb:Sanofi
|
| gptkbp:focus |
oncology
precision medicines |
| gptkbp:founded |
2014
|
| gptkbp:founder |
Martin Babler
|
| gptkbp:headquarters_location |
gptkb:Redwood_City,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Revolution Medicines, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notable_product_candidate |
gptkb:RMC-4630
RMC-6236 RMC-6291 |
| gptkbp:numberOfEmployees |
over 200
|
| gptkbp:pipeline |
PI3K inhibitors
RAS(ON) Inhibitors |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:servesArea |
gptkb:United_States
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:RVMD
|
| gptkbp:website |
https://www.revmed.com/
|
| gptkbp:bfsParent |
gptkb:RVMD
|
| gptkbp:bfsLayer |
7
|